Olfactory function in restless legs syndrome

Movement Disorders

Volumn 13, Issue 3, 1998, Pages 563-565

  Adler, Charles H ^a   Gwinn, Katrina A ^a   Newman, Stephanie ^a  

^a MAYO CLINIC   (United States)

Author keywords

Olfaction; Parkinson's disease; Restless leg syndrome

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RESTLESS LEGS SYNDROME; SMELLING DISORDER;

AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DISCRIMINATION (PSYCHOLOGY); FEMALE; HUMANS; MALE; MIDDLE AGED; NEUROLOGIC EXAMINATION; OLFACTION DISORDERS; PARKINSON DISEASE; REFERENCE VALUES; RESTLESS LEGS SYNDROME; SENSORY THRESHOLDS; SMELL;

EID: 0031945162     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130332     Document Type: Article

References (16)

1. Strang RR. The symptom of restless legs. Med J Aust 1967;24: 1211-1213.
2. Ondo W, Jankovic J. Restless legs syndrome: clinicoetiologic correlates. Neurology 1996;47:1435-1441.
3. Silber MH. Restless legs syndrome. Mayo Clin Proc 1997;72:261-264.
4. Fazzini E, Diaz R, Fahn S. Restless leg in Parkinson's disease -clinical evidence for underactivity of catecholamine neurotransmission [Abstract]. Ann Neurol 1989;26:142.
5. Walters AS, Hening WA, Kavey N, Chokroverty S, Gidro-Frank S. A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome. Ann Neurol 1988;24:455-458.
6. Doty RL, Deems DA, Stellar S. Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237-1244.
7. Doty RL, Bromley SM, Stern MB. Olfactory testing as an aid in the diagnosis of Parkinson's disease: development of optimal discrimination criteria. Neurodegeneration 1995;4:93-97.
8. Walters AS. Toward a better definition of the restless legs syndrome. Mov Disord 1995;10:634-642.
9. Fahn S, Elton RL, and members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne CD, eds. Recent Developments in Parkinson's Disease. Vol II. Florham Park, NJ: Macmillan; 1987:153-163.
10. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
11. O'Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing 1994;3:200-203.
12. Brodeur C, Montplaisir J, Godbout R, Marinier R. Treatment of restless legs syndrome and periodic movements of sleep with L-dopa: a double-blind, controlled study. Neurology 1988;38:1845-1848.
13. Lang AE. Restless legs syndrome and Parkinson's disease: insights into pathophysiology. Clin Neuropharmacol 1987;10:476-478.
14. Riley DE, Lang AE. The spectrum of levodopa-related fluctuations in Parkinson's disease. Neurology 1993;43:1459-1464.
15. Staedt J, Stoppe G, Kogler A. Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D-2 receptor alterations. Eur Arch Psychiatry Clin Neurosci 1995;245: 8-10.
16. Bucher SF, Seelos KC, Oertel WH, Reiser M, Trenkwalder C. Cerebral generators involved in the pathogenesis of the restless legs syndrome. Ann Neurol 1997;41:639-645.